JARID1A : a Novel Oncology Therapeutic Target.
Many cancers can be attributed to alterations and mutations in tumor suppressor proteins. JARID1A (Jumonji, AT-rich interactive domain 1A) also recognized as RBP2 and RBBP2 is a ubiquitously expressed nuclear protein. JARID1A binds to the retinoblastoma protein (RB) variants that modulate cellular transcription and molecular proliferation/differentiation. JARID1A has also been shown to interact with rhombotin-2, a protein implicated in T-cell mediated leukemia.
JARID1B also recognized as PLU-1 has been shown to block terminal differentiation altering cell fate.
JARID1B is over-expressed in many breast cancers and may modulate the BRCA1 and HOXA5 tumor suppressors.